✦ LIBER ✦

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

✍ Scribed by W. G. Dixon; K. D. Watson; M. Lunt; K. L. Hyrich; A. J. Silman; D. P. M. Symmons

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 82 KB
Volume: 56
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.22809

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of anti–tumor necrosis factor

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

✍ W. G. Dixon; K. D. Watson; M. Lunt; L. K. Mercer; British Society For Rheumatolo 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 111 KB 👁 2 views

No evidence of association between anti–

No evidence of association between anti–tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Mark Lunt; Kath D. Watson; William G. Dixon; British Society for Rheumatology Bi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Objective To study the association between anti–tumor necrosis factor (anti-TNF) therapy and mortality in a national cohort of patients with rheumatoid arthritis. ## Methods We prospectively followed up 12,672 patients who were beginning anti-TNF therapy and 3,522 biologic-naive patients recei

Rates of serious infection, including si

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

✍ W. G. Dixon; K. Watson; M. Lunt; K. L. Hyrich; A. J. Silman; D. P. M. Symmons 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

Outcomes after switching from one anti–t

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

✍ Kimme L. Hyrich; Mark Lunt; Kath D. Watson; Deborah P. M. Symmons; Alan J. Silma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) who experience treatment failure with one anti–tumor necrosis factor (anti‐TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti‐TNF agent, although the benefits of switching are unknown. The pres

An alternative, autonomic rationale for

An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti–tumor necrosis factor therapy: Comment on the article by Dixon et al

✍ Andrew J. Holman 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 32 KB 👁 2 views

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods